Search

Your search keyword '"Boffa, Jean-Jacques"' showing total 528 results
Start Over Author "Boffa, Jean-Jacques"
528 results on '"Boffa, Jean-Jacques"'

101. Prognostic Factors in Anti-glomerular Basement Membrane Disease: A Multicenter Study of 119 Patients

Author

Marques, Cindy, primary, Carvelli, Julien, additional, Biard, Lucie, additional, Faguer, Stanislas, additional, Provôt, François, additional, Matignon, Marie, additional, Boffa, Jean-Jacques, additional, Plaisier, Emmanuelle, additional, Hertig, Alexandre, additional, Touzot, Maxime, additional, Moranne, Olivier, additional, Belenfant, Xavier, additional, Annane, Djillali, additional, Quéméneur, Thomas, additional, Cadranel, Jacques, additional, Izzedine, Hassan, additional, Bréchot, Nicolas, additional, Cacoub, Patrice, additional, Piedrafita, Alexis, additional, Jourde-Chiche, Noémie, additional, and Saadoun, David, additional

Published
2019
Full Text
View/download PDF

103. Fasting Urinary Osmolality, CKD Progression, and Mortality: A Prospective Observational Study

Author

Tabibzadeh, Nahid, primary, Wagner, Sandra, additional, Metzger, Marie, additional, Flamant, Martin, additional, Houillier, Pascal, additional, Boffa, Jean-Jacques, additional, Vrtovsnik, Francois, additional, Thervet, Eric, additional, Stengel, Bénédicte, additional, Haymann, Jean-Philippe, additional, Livrozet, Marine, additional, Letavernier, Emmanuel, additional, Ronco, Pierre, additional, Fessi, Hafedh, additional, Vidal-Petiot, Emmanuelle, additional, Daugas, Eric, additional, du Halgouet, Caroline, additional, de La Faille, Renaud, additional, Maruani, Gerard, additional, Vallet, Marion, additional, Nicolet-Barousse, Laurence, additional, Karras, Alexandre, additional, and Jacquot, Christian, additional

Published
2019
Full Text
View/download PDF

104. Thrombotic microangiopathy associated with anti-neutrophil cytoplasmic antibody-associated vasculitis: a French nationwide retrospective case–control study and literature review

Author

Dellal, Azeddine, primary, Bige, Naike, additional, Hilliquin, Pascal, additional, Boffa, Jean-Jacques, additional, Rondeau, Eric, additional, Hatron, Pierre Yves, additional, Deligny, Christophe, additional, Bally, Stephane, additional, Maury, Eric, additional, Veyradier, Agnes, additional, Buob, David, additional, Fain, Olivier, additional, Coppo, Paul, additional, and Mekinian, Arsène, additional

Published
2019
Full Text
View/download PDF

105. Outcomes of Older Patients (≥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients

Author

Colliou, Eloïse, primary, Karras, Alexandre, additional, Boffa, Jean-Jacques, additional, Ribes, David, additional, Garrouste, Cyril, additional, Quintrec, Moglie, additional, Daugas, Eric, additional, Huart, Antoine, additional, Ducloux, Didier, additional, Hummel, Aurélie, additional, Ferrandiz, Inès, additional, Demoulin, Nathalie, additional, Jourde-Chiche, Noémie, additional, Chauveau, Dominique, additional, Audard, Vincent, additional, and Faguer, Stanislas, additional

Published
2019
Full Text
View/download PDF

107. Less arterial stiffness in kidney transplant recipients than chronic kidney disease patients matched for renal function.

Author

Cheddani, Lynda, Haymann, Jean Philippe, Liabeuf, Sophie, Tabibzadeh, Nahid, Boffa, Jean-Jacques, Letavernier, Emmanuel, Essig, Marie, Drüeke, Tilman B, Delahousse, Michel, Massy, Ziad A, and Group, the NephroTest Study

Subjects
CHRONIC kidney failure, ARTERIAL diseases, KIDNEY transplantation, CHRONICALLY ill, KIDNEY physiology
Abstract

Background Chronic kidney disease is associated with a high cardiovascular risk. Compared with glomerular filtration rate–matched CKD patients (CKDps), we previously reported a 2.7-fold greater risk of global mortality among kidney transplant recipients (KTRs). We then examined aortic stiffness [evaluated by carotid–femoral pulse wave velocity (CF-PWV)] and cardiovascular risk in KTRs compared with CKDps with comparable measured glomerular filtration rate (mGFR). Methods We analysed CF-PWV in two cohorts: TransplanTest (KTRs) and NephroTest (CKDps). Propensity scores were calculated including six variables: mGFR, age, sex, mean blood pressure (MBP), body mass index (BMI) and heart rate. After propensity score matching, we included 137 KTRs and 226 CKDps. Descriptive data were completed by logistic regression for CF-PWV values higher than the median (>10.6 m/s). Results At 12 months post-transplant, KTRs had significantly lower CF-PWV than CKDps (10.1 versus 11.0 m/s, P = 0.008) despite no difference at 3 months post-transplant (10.5 versus 11.0 m/s, P = 0.242). A lower occurrence of high arterial stiffness was noted among KTRs compared with CKDps (38.0% versus 57.1%, P < 0.001). It was especially associated with lower mGFR, older age, higher BMI, higher MBP, diabetes and higher serum parathyroid hormone levels. After adjustment, the odds ratio for the risk of high arterial stiffness in KTRs was 0.40 (95% confidence interval 0.23–0.68, P < 0.001). Conclusions Aortic stiffness was significantly less marked in KTRs 1 year post-transplant than in CKDps matched for GFR and other variables. This observation is compatible with the view that the pathogenesis of post-transplant cardiovascular disease differs, at least in part, from that of CKD per se. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

108. Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases.

Author

Durel, Cécile-Audrey, Sinico, Renato A, Teixeira, Vitor, Jayne, David, Belenfant, Xavier, Marchand-Adam, Sylvain, Pugnet, Gregory, Gaultier, Jacques, Gallou, Thomas Le, Titeca-Beauport, Dimitri, Agard, Christian, Barbet, Christelle, Bardy, Antoine, Blockmans, Daniel, Boffa, Jean-Jacques, Bouet, Julien, Cottin, Vincent, Crabol, Yoann, Deligny, Christophe, and Essig, Marie

Subjects
BIOPSY, KIDNEYS, MEDICAL cooperation, PERIPHERAL neuropathy, RESEARCH, CHURG-Strauss syndrome, GRANULOMATOSIS with polyangiitis, RETROSPECTIVE studies, DESCRIPTIVE statistics, ANTINEUTROPHIL cytoplasmic antibodies
Abstract

Objective Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic small-vessel vasculitis characterized by asthma, hypereosinophilia and ANCA positivity in 40% of patients. Renal involvement is rare and poorly described, leading to this renal biopsy-proven based study in a large EGPA cohort. Methods We conducted a retrospective multicentre study including patients fulfilling the 1990 ACR criteria and/or the 2012 revised Chapel Hill Consensus Conference criteria for EGPA and/or the modified criteria of the MIRRA trial, with biopsy-proven nephropathy. Results Sixty-three patients [27 women, median age 60 years (18–83)] were included. Renal disease was present at vasculitis diagnosis in 54 patients (86%). ANCA were positive in 53 cases (84%) with anti-MPO specificity in 44 (83%). All patients had late-onset asthma. Peripheral neuropathy was present in 29 cases (46%), alveolar haemorrhage in 10 (16%). The most common renal presentation was acute renal failure (75%). Renal biopsy revealed pauci-immune necrotizing GN in 49 cases (78%). Membranous nephropathy (10%) and membranoproliferative GN (3%) were mostly observed in ANCA-negative patients. Pure acute interstitial nephritis was found in six cases (10%); important interstitial inflammation was observed in 28 (44%). All patients received steroids with adjunctive immunosuppression in 54 cases (86%). After a median follow-up of 51 months (1–296), 58 patients (92%) were alive, nine (14%) were on chronic dialysis and two (3%) had undergone kidney transplantation. Conclusion Necrotizing pauci-immune GN is the most common renal presentation in ANCA-positive EGPA. ANCA-negative patients had frequent atypical renal presentation with other glomerulopathies such as membranous nephropathy. An important eosinophilic interstitial infiltration was observed in almost 50% of cases. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

109. Recommandations des pratiques cliniques pour la prise en charge des patients diabétiques et ayant une maladie rénale chronique stade 3B ou plus (DFGe < 45 mL/min/1,73 m 2 ). Traduction française

Author

Jourde-Chiche, Noemie, Guerrot, Dominique, Chauveau, Dominique, Boffa, Jean-Jacques, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and DIGNAT-GEORGE, Françoise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

110. Report on chronic dialysis in France in 2016

Author

Bouchet, Jean-Louis, Bourdenx, Jean-Philippe, Brasseur, Jose, Brillet, Georges, Chanliau, Jacques, Chantrel, Francois, Chauveau, Dominique, Chazot, Charles, Cluzel, Pascal, Durand, Pierre-Yves, Eladari, Dominique, Esnault, Vincent, Essig, Marie, Fouque, Denis, Frayssinet, Raymond, Fremeaux-Bacchi, Veronique, Frimat, Luc, Goupy, Christophe, Hannedouche, Thierry, Hazzan, Marc, Hourmant, Maryvonne, Jean, Guillaume, Jerome, Eric, Joly, Dominique, Juquel, Jean-Pierre, Kerkeni, Nadia, Kunz, Kristian, Laville, Maurice, Lobbedez, Thierry, Mamzer-Bruneel, Marie-France, Mariat, Christophe, Menoyo-Calonge, Victorio, Mercadal, Lucile, Meskine, Mohamed, Meulders, Quentin, Mourey-Epron, Catherine, Peraldi, Marie-Noelle, Perrone, Bruno, Rieu, Philippe, Sahali, Djillali, Vela, Carlos, Verger, Christian, Vrtovsnik, Francois, Teta, Daniel, Chauveau, Philippe, Cridlig, Joelle, Fessi, Hafedh, Guerin, Alain, Henri, Patrick, Imiela, Jean-Paul, Issad, Belkacem, Le Roy, Frank, Poux, Jean-Michel, Ryckelynck, Jean-Philippe, Siohan, Pascale, Toledano, Daniel, Di, Societe Francophone Nephrologie, Brunet, Philippe, Combe, Christian, Choukroun, Gabriel, Moulin, Bruno, Arkouche, Walid, Bataille, Pierre, Caillette-Beaudoin, Agnes, Giaime, Philippe, Pietrement, Christine, Stroumza, Paul, Azar, Raymond, Boffa, Jean-Jacques, Centre de traitement des maladies rénales, CTMR Saint-Augustin, Service de Néphrologie [Bois-Bernard], Hôpital privé Bois-Bernard, Association Lorraine pour le Traitement de l'Insuffisance Rénale (ALTIR), Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Système macromoléculaires et immunovirologie humaine, IFR128-Centre National de la Recherche Scientifique (CNRS)-bioMérieux SA, Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de néphrologie, Centre Hospitalier Universitaire de Nice (CHU Nice), Service de Néphrologie, Dialyse, Transplantations [CHU Limoges], CHU Limoges, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'immunologie [HEGP, Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Complément et Maladies (CRC - Inserm U1138), Centre de Recherche des Cordeliers (CRC), Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Néphrologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de néphrologie et hémodialyse [CHU de Strasbourg], CHU Strasbourg, Service de Néphrologie et Transplantation rénale [CHRU-lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut de transplantation urologie-néphrologie (ITUN), Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre National de la Recherche Scientifique (CNRS), Service d'Urgences et de Réanimation médicale polyvalente, Hôpital Saint Philibert, Service de Néphrologie-Dialyse-Transplantation rénale [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Registre de Dialyse Péritonéale de Langue Française et Hémodialyse à Domicile [Pontoise] (RDPLF-HDD), Service de néphrologie adultes [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Néphrologie [Avignon], Centre Hospitalier Henri Duffaut (Avignon), Service de maladies infectieuses et tropicales [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre Hospitalier Universitaire de Reims (CHU Reims), INSERM U955, équipe 21, Service de néphrologie et transplantation, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Claude Huriez [Lille], CHU Lille, Service de Néphrologie [Bichat - Claude Bernard], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Centre Hospitalier Universitaire Vaudois (CHUV), Service de Néphrologie-transplantation-dialyse [Bordeaux], CHU Bordeaux [Bordeaux], Fibrose hépatique et cancer du foie, Université Bordeaux Segalen - Bordeaux 2-IFR66-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU), Hydrosystèmes et Bioprocédés (UR HBAN), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Centre Universitaire des Maladies Rénales [CHU Caen] (CUMR Caen), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université - Faculté de Médecine (SU FM), Service de Néphrologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Néphrologie CH Quimper, Service de Néphrologie CH QUIMPER, Institut des Neurosciences Paris-Saclay (NeuroPSI), Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS), Département de Recherche en Ingénierie des Véhicules pour l'Environnement [Nevers] (DRIVE), Université de Bourgogne (UB)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Bioingénierie tissulaire (BIOTIS), Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service de Néphrologie et Transplantation, Association pour l'Utilisation du Rein Artificiel Région Lyonnaise (AURAL), Service de Néphrologie [CH Boulogne-sur-Mer], Centre Hospitalier Boulogne-sur-mer, Hôpital Lucien Hussel Vienne [Vienne, France] (HLHV), Aix Marseille Université (AMU), Service de Néphrologie [CH Dunkerque], CH Dunkerque, Remodelage et Reparation du Tissu Renal, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Morphodynamique Continentale et Côtière (M2C), Normandie Université (NU)-Normandie Université (NU)-Institut national des sciences de l'Univers (INSU - CNRS)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Etienne, Service de Néphrologie et Dialyses [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Service de Néphrologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Département de Néphrologie = Service de Néphrologie et Dialyses [CHU Tenon], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience; The report on dialysis in France in 2016 from the French Speaking Society of Nephrology Dialysis and Transplantation (SFNDT) provides an exhaustive and documented inventory on dialysis in France. It underlines the organizations that are important in 2016 to maintain a high quality dialysis. Several measures are proposed to maintain and improve the care of dialysis in France: (I) The regulation of dialysis treatment in France must be maintained; (2) a burden of care indicator is proposed to ensure that patients requiring the most care are treated in the centers. Proposals are also made to stimulate peritoneal dialysis offers, (3) to improve the calculation of the cost of dialysis and warn against lower reimbursement rates of dialysis, (4) to reduce transport costs by minimizing transport by ambulance (5). The SFNDT recalls recent recommendations concerning access to the renal transplant waiting list, are recalled; (6) as well as recommendations that require waiting until clinical signs are present to start dialysis (7). The SFNDT makes the proposal to set up advanced renal failure units. These units are expected to develop care that is not supported today: consultation with a nurse, a dietician, a social worker or psychologist, palliative care, and coordination (8). Finally, the financial and human resources for pediatric dialysis should be maintained. (C) 2017 Published by Elsevier Masson SAS on behalf of Association Societe de nephrologie.

Published
2017

111. Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study

Author

Wagner, Sandra, Metzger, Marie, Flamant, Martin, Houillier, Pascal, Haymann, Jean-Philippe, Vrtovsnik, François, Thervet, Eric, Boffa, Jean-Jacques, Massy, Ziad, Stengel, Bénédicte, Rossignol, Patrick, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Saclay, French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Explorations fonctionnelles néphrologie - Rénales [AP-HP Hôpital Bichat-Claude-Bernard, Paris], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche des Cordeliers (CRC), Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiologie - Explorations fonctionnelles [AP-HP HEGP, Paris], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Néphrologie [Boulogne-Billancourt], Hôpital Ambroise Paré [AP-HP], Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), The NephroTest cohort study was supported by grants from Inserm GIS-IreSP AO 8113LS TGIR, French Ministry of Health AOM 09114 and AOM 10245, Inserm AO8022LS, Agence de la Biomédecine R08156LL, AURA, and Roche 2009–152-447G., The NephroTest study group : Letavernier E, Ronco P, Fessi H, Daugas E, du Halgouet C, de La Faille R, d'Auzac C, Maruani G, Vallet M, Nicolet-Barousse L, Roland M, Jacquot C., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Néphrologie et Dialyses [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Centre de recherche en épidémiologie et santé des populations ( CESP ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), French-Clinical Research Infrastructure Network - F-CRIN [Paris] ( Cardiovascular & Renal Clinical Trialists - CRCT ), Centre de Recherche des Cordeliers ( CRC ), Université Paris Diderot - Paris 7 ( UPD7 ) -École pratique des hautes études ( EPHE ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Paris-Centre de Recherche Cardiovasculaire ( PARCC - U970 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Européen Georges Pompidou [APHP] ( HEGP ), AP-HP Hôpital Ambroise Paré (Boulogne-Billancourt), CIC-Nancy, Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), BMC, BMC, Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Service de Département de Néphrologie = Service de Néphrologie et Dialyses [CHU Tenon], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
[SDV] Life Sciences [q-bio], Plasma potassium, Cardiovascular mortality, [ SDV ] Life Sciences [q-bio], Chronic kidney disease, [SDV]Life Sciences [q-bio], End-stage kidney disease, Hyperkalemia, Hypokalemia, Mortality
Abstract

International audience; AbstractBackgroundLow and high blood potassium levels are common and were both associated with poor outcomes in patients with chronic kidney disease (CKD). Whether such relationships may be altered in CKD patients receiving optimized nephrologist care is unknown.MethodsNephroTest is a hospital-based prospective cohort study that enrolled 2078 nondialysis patients (mean age: 59 ± 15 years, 66% men) in CKD stages 1 to 5 who underwent repeated extensive renal tests including plasma potassium (PK) and glomerular filtration rate (GFR) measured (mGFR) by 51Cr-EDTA renal clearance. Test reports included a reminder of recommended targets for each abnormal value to guide treatment adjustment. Main outcomes were cardiovascular (CV) and all-cause mortality before end-stage kidney disease (ESKD), and ESKD.ResultsAt baseline, median mGFR was 38.4 mL/min/1.73m2; prevalence of low PK (5 mmol/L) 6.4%; 74.4% of patients used angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). After excluding 137 patients with baseline GFR

Published
2016

113. Association of a Low-Protein Diet With Slower Progression of CKD

Author

Metzger, Marie, primary, Yuan, Wen Lun, additional, Haymann, Jean-Philippe, additional, Flamant, Martin, additional, Houillier, Pascal, additional, Thervet, Eric, additional, Boffa, Jean-Jacques, additional, Vrtovsnik, François, additional, Froissart, Marc, additional, Bankir, Lise, additional, Fouque, Denis, additional, and Stengel, Bénédicte, additional

Published
2018
Full Text
View/download PDF

114. Acute metabolic acidosis in a GLUT2-deficient patient with Fanconi-Bickel syndrome: new pathophysiology insights

Author

Mihout, Fabrice, Devuyst, Olivier, Bensman, Albert, Brocheriou, Isabelle, Ridel, Christophe, Wagner, Carsten A., Mohebbi, Nilufar, Boffa, Jean-Jacques, Plaisier, Emmanuelle, Ronco, Pierre, Mihout, Fabrice, Devuyst, Olivier, Bensman, Albert, Brocheriou, Isabelle, Ridel, Christophe, Wagner, Carsten A., Mohebbi, Nilufar, Boffa, Jean-Jacques, Plaisier, Emmanuelle, and Ronco, Pierre

Abstract

Fanconi-Bickel syndrome is a rare autosomal-recessive disorder caused by mutations in the SLC2A2 gene coding for the glucose transporter protein 2 (GLUT2). Major manifestations include hepatomegaly, glucose intolerance, post-prandial hypoglycaemia and renal disease that usually presents as proximal tubular acidosis associated with proximal tubule dysfunction (renal Fanconi syndrome). We report a patient harbouring a homozygous mutation of SLC2A2 who presented a dramatic exacerbation of metabolic acidosis in the context of a viral infection, owing to both ketosis and major urinary bicarbonate loss. The kidney biopsy revealed nuclear and cytoplasmic accumulation of glycogen in proximal tubule cells, a lack of expression of GLUT2, and major defects of key proteins of the proximal tubule such as megalin, cubilin and the B2 subunit of H+-ATPase. These profound alterations of the transport systems most likely contributed to proximal tubule alterations and profound bicarbonate loss

Published
2017

115. Long-term outcomes of the WEGENT trial on remission-maintenance for granulomatosis with polyangiitis or microscopic polyangiitis

Author

Puéchal, Xavier, Pagnoux, Christian, Perrodeau, Elodie, Hamidou, Mohamed, Boffa, Jean-Jacques, Kyndt, Xavier, Lifermann, François, Papo, Thomas, Merrien, Dominique, Smail, Amar, Delaval, Philippe, Hanrotel-Saliou, Catherine, Imbert, Bernard, Khouatra, Chahéra, Lambert, Marc, Leské, Charles, Ly, Kim, Pertuiset, Edouard, Roblot, Pascal, Ruivard, Marc, Subra, Jean-François, Viallard, Jean-François, Terrier, Benjamin, Cohen, Pascal, Mouthon, Luc, Le Jeunne, Claire, Ravaud, Philippe, Guillevin, Loïc, Institut Cochin ( UM3 (UMR 8104 / U1016) ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Equipe 5 : METHODS - Méthodes de l’évaluation thérapeutique des maladies chroniques ( CRESS - U1153 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité ( CRESS (U1153 / UMR_A 1125) ), Institut National de la Recherche Agronomique ( INRA ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut National de la Recherche Agronomique ( INRA ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de médecine interne [Nantes], Université de Nantes ( UN ) -Hôtel-Dieu-Centre hospitalier universitaire de Nantes ( CHU Nantes ), Remodelage et Reparation du Tissu Renal, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Néphrologie, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Service de médecine interne et néphrologie, CH Valenciennes, Service de Médecine Interne [Dax], Hôpital Dax, Hôpital Bichat - Claude Bernard, Centre Hospitalier Compiègne-Noyon, Service de Néphrologie - Médecine Interne, CHU Amiens-Picardie-Hôpital Sud, Institut de recherche, santé, environnement et travail ( Irset ), Université d'Angers ( UA ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -École des Hautes Études en Santé Publique [EHESP] ( EHESP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ) -Université des Antilles ( UA ), Service de pneumologie, CHU Pontchaillou [Rennes], Immunologie et Pathologie ( EA2216 ), Université de Brest ( UBO ) -IFR148, CHRU - Service de néphrologie, dialyse et transplantation rénale, Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), CHU Grenoble, Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon ( HCL ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), CH Cholet, CHU Limoges, Hopital Réné Dubos, Service de Médecine Interne, Centre hospitalier universitaire de Poitiers ( CHU Poitiers ), CHU Estaing [Clermont-Ferrand], Service de Néphrologie [Angers], Université d'Angers ( UA ) -CHU Angers, Service de Médecine Interne et Maladies Infectieuses [Pessac], CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], CHU Cochin [AP-HP], Club Rhumatismes et Inflammation, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Equipe 5 : METHODS - Méthodes de l’évaluation thérapeutique des maladies chroniques (CRESS - U1153), Université Paris Descartes - Paris 5 (UPD5)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Sorbonne Paris Cité (USPC), Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [APHP], Centre Hospitalier de Dax, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Amiens-Picardie-hôpital Sud, Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), CHU Clermont-Ferrand, Hôpital Cochin [AP-HP], Hospices Civils de Lyon (Délégation à la Recherche Clinique, Lyon, France, Trial no. 97.129), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Jonchère, Laurent

Subjects
[SDV] Life Sciences [q-bio], [ SDV ] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

International audience; Objective - Findings from the WEGENT trial and other short-term studies have suggested that azathioprine (AZA) or methotrexate (MTX) could effectively maintain remission of granulomatosis with polyangiitis (Wegener's) (GPA) or microscopic polyangiitis (MPA). This study was undertaken to examine whether differences in rates of relapse or adverse events would appear after discontinuation of these 2 maintenance regimens, when assessed over a longer followup period. Methods - Long-term outcomes in patients enrolled in the WEGENT trial were analyzed according to their randomized treatment group (AZA or MTX). Parameters at trial entry were evaluated as potential prognostic factors for death, relapse, or damage in multivariate models. Results - Data from 10 years of followup were available for 112 (88.8%) of the 126 original trial participants. The median followup time was 11.9 years (95% confidence interval [95% CI] 11.3-12.5 years). In patients receiving AZA and those receiving MTX, the 10-year overall survival rates were 75.1% (95% CI 64.8-86.9%) and 79.9% (95% CI 70.3-90.8%) (P = 0.56), respectively, and relapse-free survival rates were 26.3% (95% CI 17.3-40.1%) and 33.5% (95% CI 23.5-47.7%) (P = 0.29), respectively. No between-treatment differences were observed with regard to rates of relapse, adverse events, damage, survival without severe side effects, and survival without relapse and severe side effects. In analyses limited to the 97 patients with GPA, no between-treatment differences in survival rates were observed. The 10-year relapse-free survival rate was lower in patients with GPA than in patients with MPA. However, in the multivariate analysis, anti-proteinase 3 antineutrophil cytoplasmic antibody (ANCA) positivity, and not GPA, was retained as being independently associated with the relapse rate. Conclusion - The results of this long-term analysis confirm that AZA and MTX are comparable treatment options for maintaining remission of GPA or MPA. Despite achieving good overall survival with these treatments, relapse rates, adverse events, and damage remain matters of concern and further studies are needed to reduce their frequency in these ANCA-associated vasculitides.

Published
2016

117. Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease

Author

Dauvergne, Maxime, Moktefi, Anissa, Rabant, Marion, Vigneau, Cécile, Kofman, Tomek, Burtey, Stéphane, Corpechot, Christophe, Stehlé, Thomas, Desvaux, Dominique, Rioux-Leclercq, Nathalie, Rouvier, Philippe, Knebelmann, Bertrand, Boffa, Jean-Jacques, Frouget, Thierry, Daugas, Eric, Jablonski, Mathieu, Dahan, Karine, Brochériou, Isabelle, Remy, Philippe, Grimbert, Philippe, Lang, Philippe, Chazouilleres, Oliver, Sahali, Dil, Audard, Vincent, INSERM U955, équipe 21, Service de néphrologie et transplantation, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pontchaillou [Rennes], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Vascular research center of Marseille (VRCM), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), CHU Pitié-Salpêtrière [AP-HP], Service de néphrologie adultes [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Remodelage et Reparation du Tissu Renal, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1599, Centre National de la Recherche Scientifique (CNRS), CHU Tenon [AP-HP], Service de néphrologie [CHU Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Henri Mondor [Créteil], Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Service d'hépatologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de pathologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Néphrologie et Dialyses [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Service de Pathologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut Mondor de Recherche Biomédicale (IMRB), Service d'hépatologie [Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Sorbonne Université (SU)-CHU Saint-Antoine [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Tenon [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'Hépato-gastro-entérologie [CHU Saint-Antoine], Service d'Anatomie et cytologie pathologiques = Service de Pathologie [CHU Pitié-Salpêtrière] (ACP), Service de Département de Néphrologie = Service de Néphrologie et Dialyses [CHU Tenon], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)

Subjects
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; The association between membranous nephropathy (MN) and immunological disorder-related liver disease has not been extensively investigated, and the specific features of this uncommon association, if any, remain to be determined.We retrospectively identified 10 patients with this association. We aimed to describe the clinical, biological, and pathological characteristics of these patients and their therapeutic management. The possible involvement of the phospholipase A2 receptor (PLA2R) in these apparent secondary forms of MN was assessed by immunohistochemistry with renal and liver biopsy specimens.The mean delay between MN and liver disease diagnoses was 3.9 years and the interval between the diagnosis of the glomerular and liver diseases was

Published
2015

119. Prevalence of APOL1 Variants in Persons with Proteinuric CKD

Author

Bramham, Kate, Knebelmann, Bertrand, Audard, Vincent, Boffa, Jean-Jacques, Echeverri, Diego, Mccafferty, Kieran, Powell, Thomas, Provenzano, Christopher, Shahid, Nauman, Zaidan, Mohamad, Torres, Pablo A. Urena, Mastroianni-Kirsztajn, Gianna, Zamauskaite, Aurelia, Delestre-Levai, Irisz K., Bauman, John, Yang, Yuan, Krause, Silva, Ferreira, Anna, Egbuna, Ogo I., and Chertow, Glenn

Published
2023
Full Text
View/download PDF

126. Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study.

Author

Jachiet, Vincent, Mekinian, Arsène, Carrat, Fabrice, Grignano, Eric, Retbi, Aurelia, Boffa, Jean-Jacques, Ronco, Pierre, Rondeau, Eric, Sellam, Jérémie, Berenbaum, Francis, Chazouillères, Olivier, Capron, Jean, Alamowitch, Sonia, Chasset, Francois, Frances, Camille, Coppo, Paul, Fain, Olivier, and on behalf of French Network of systemic and immune disorders associated with hemopathies and cancer (MINHEMON)

Subjects
LYMPHOMAS, AUTOIMMUNITY, HODGKIN'S disease, B cell lymphoma, CHRONIC lymphocytic leukemia, PATIENTS
Abstract

This French multicenter retrospective cohort study aimed to describe the autoimmune manifestations (AIMs) associated with lymphoma among patients hospitalized between 2005 and 2016 in three French University Hospitals. Among 2503 patients with lymphoma, 108 (4.3%) had AIMs, mostly autoimmune cytopenias (71.3%), neurological diseases (10.2%), kidney diseases (6.5%), systemic vasculitis (5.6%) and others. As compared with the 2395 lymphoma patients without AIMs, those with AIMs were older (p = .01), more frequently had B-cell chronic lymphocytic leukemia (p < .01) and less frequently diffuse large B-cell lymphomas (p = .01) and Hodgkin lymphoma (p = .01). The 5-year overall survival with lymphoma was 65% and 79% (p = .03) with and without AIMs. This large cohort study shows that various types of AIMs, mostly cytopenias, could be associated with lymphoma and affect the overall outcome with lymphoma, in particular for B-cell non-Hodgkin lymphoma (p = .01) and T-cell non-Hodgkin lymphoma (p = .01), with no survival difference noted for other types of lymphoma (p = .2). [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

127. [IgG4-related disease and renal and urological involvement]

Author

Zaidan, Mohamad, Ebbo, Mikael, Brochériou, Isabelle, Ronco, Pierre, Schleinitz, Nicolas, Boffa, Jean-Jacques, Remodelage et Reparation du Tissu Renal, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Néphrologie et Dialyses [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Service d'anatomie pathologique [CHU Tenon], Aix Marseille Université (AMU), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), RONCO, Pierre, Service de Département de Néphrologie = Service de Néphrologie et Dialyses [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Service d'Anatomie et cytologie pathologiques [CHU Tenon]

Subjects
MESH: Glomerulonephritis, Membranous, pancreatitis, Kidney, Glomerulonephritis, Membranous, MESH: Retroperitoneal Fibrosis, MESH: Aortitis, aneurysms, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Humans, Tubulointerstitial nephritis, IgG4-related disease, Glucocorticoids, IgG4, MESH: Immunoglobulin G, MESH: Humans, Aortitis, Aortic, MESH: Kidney, Retroperitoneal fibrosis, Aortitis Autoimmune, Aortic Aneurysm, Prostatitis, MESH: Aortic Aneurysm, Immunoglobulin G, [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Nephritis, Interstitial, MESH: Glucocorticoids, MESH: Nephritis, Interstitial
Abstract

International audience; Hyper-IgG4 syndrome, or IgG4-related disease, is an emerging disorder, involving one or more organ(s), and characterized by "storiform" fibrosis and inflammatory lesions with a predominance of IgG4+ plasma cells and increased IgG4 serum levels. Since the first report of auto-immune pancreatitis, numerous organ lesions have been reported and have been found to occur in a same patient including: sialadenitis, dacryoadenitis, lymphadenopathy, liver and biliary tract involvement, and renal and retroperitoneal lesions. Renal involvement was first described in 2004 and usually presents as functional and/or morphological abnormalities. In most cases, renal pathological analysis reveals tubulointerstitial nephritis that is rarely associated with glomerular lesions. Retroperitoneal fibrosis is also a typical feature that may be associated with periaortitis or inflammatory abdominal aortic aneurysm. First line treatment is based on corticosteroid therapy. Short-term outcome is usually favorable. However, patients should be carefully monitored for relapses and long-term complications. Although the multiple organ lesions share common clinical, biological, radiological and pathological features, no consensus diagnostic criteria have yet been validated for IgG4-related disease. Ruling out differential diagnoses is thus mandatory. Our literature review provides nephrologists, urologists and pathologists with key elements that will help in the early diagnosis and proper management of this new and emerging disorder.

Published
2012

128. Timing and determinants of erythropoietin deficiency in chronic kidney disease. : Erythropoietin and chronic kidney disease

Author

Mercadal, Lucile, Metzger, Marie, Casadevall, Nicole, Haymann, Jean-Philippe, Karras, Alexandre, Boffa, Jean-Jacques, Flamant, Martin, Vrtovsnik, François, Stengel, Bénédicte, Froissart, Marc, Centre de recherche en épidémiologie et santé des populations ( CESP ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Hématopoïèse normale et pathologique, Université Paris-Sud - Paris 11 ( UP11 ) -Institut Gustave Roussy ( IGR ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Remodelage et Reparation du Tissu Renal, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de Physiologie [Tenon], Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Service de Néphrologie [HEGP], Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Service de Néphrologie et Dialyses [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Service de Physiologie [Bichat-Claude Bernard], Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Immunopathologie rénale, récepteurs et inflammation, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de Néphrologie [Bichat-Claude Bernard], Service de physiologie, explorations fonctionnelles et radioisotopes [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), The NephroTest CKD cohort study is supported by grants from: Inserm GIS-IReSP AO - 8113LS TGIR (BS), French Ministry of Health AOM 09114 (MF), Inserm AO 8022LS (BS), Agence de la Biomédecine R0 8156LL (BS), AURA (MF) and Roche 2009-152-447G (MF). The Nephrotest initiative was also sponsored by unrestricted grants from F.Hoffman-La Roche Ltd. (LM)., Nephrotest Study Group, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Gustave Roussy (IGR)-Université Paris-Sud - Paris 11 (UP11), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
MESH : Male, MESH : Aged, MESH : Hemoglobins, MESH: Multivariate Analysis, MESH : Chronic Disease, hemic and lymphatic diseases, MESH : Erythropoietin, MESH : Middle Aged, MESH : Female, MESH: Erythropoietin, MESH: Aged, MESH: Kidney Diseases, MESH: Middle Aged, MESH: Humans, MESH: Chronic Disease, MESH: Time Factors, MESH : Humans, MESH : Glomerular Filtration Rate, MESH : Multivariate Analysis, MESH: Adult, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Adult, MESH: Male, MESH: Glomerular Filtration Rate, MESH: Hemoglobins, MESH : Kidney Diseases, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Female, MESH : Time Factors
Abstract

International audience; BACKGROUND AND OBJECTIVES: Anemia in patients with CKD is highly related to impaired erythropoietin (EPO) response, the timing and determinants of which remain unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study measured EPO levels and studied their relation to GFR measured by 51Cr-EDTA renal clearance (mGFR) in 336 all-stage CKD patients not receiving any erythropoiesis-stimulating agent. RESULTS: In patients with anemia defined by World Health Organization criteria (hemoglobin [Hb] 30 ml/min per 1.73 m(2), whereas they were not correlated when mGFR was 30 ml/min per 1.73 m(2) calls for other explanatory factors.

Published
2012

130. Pseudo-Peritoneal Carcinomatosis Presentation of a Crystal-Storing Histiocytosis With an Unmutated Monoclonal κ Light Chain

Author

Aline-Fardin, Aude, primary, Bender, Sebastien, additional, Fabiani, Bettina, additional, Buob, David, additional, Brahimi, Said, additional, Verpont, Marie Christine, additional, Mothy, Mohamad, additional, Ronco, Pierre, additional, Boffa, Jean Jacques, additional, Aucouturier, Pierre, additional, and Garderet, Laurent, additional

Published
2015
Full Text
View/download PDF

131. Urinary ammonia and long-term outcomes in chronic kidney disease

Author

Vallet, Marion, primary, Metzger, Marie, additional, Haymann, Jean-Philippe, additional, Flamant, Martin, additional, Gauci, Cédric, additional, Thervet, Eric, additional, Boffa, Jean-Jacques, additional, Vrtovsnik, François, additional, Froissart, Marc, additional, Stengel, Bénédicte, additional, and Houillier, Pascal, additional

Published
2015
Full Text
View/download PDF

133. Acute metabolic acidosis in a GLUT2-deficient patient with Fanconi-Bickel syndrome: new pathophysiology insights

Author

UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Mihout, Fabrice, Devuyst, Olivier, Bensman, Albert, Brocheriou, Isabelle, Ridel, Christophe, Wagner, Carsten A., Mohebbi, Nilufar, Boffa, Jean-Jacques, Plaisier, Emmanuelle, Ronco, Pierre, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Mihout, Fabrice, Devuyst, Olivier, Bensman, Albert, Brocheriou, Isabelle, Ridel, Christophe, Wagner, Carsten A., Mohebbi, Nilufar, Boffa, Jean-Jacques, Plaisier, Emmanuelle, and Ronco, Pierre

Abstract

Fanconi-Bickel syndrome is a rare autosomal-recessive disorder caused by mutations in the SLC2A2 gene coding for the glucose transporter protein 2 (GLUT2). Major manifestations include hepatomegaly, glucose intolerance, post-prandial hypoglycaemia and renal disease that usually presents as proximal tubular acidosis associated with proximal tubule dysfunction (renal Fanconi syndrome). We report a patient harbouring a homozygous mutation of SLC2A2 who presented a dramatic exacerbation of metabolic acidosis in the context of a viral infection, owing to both ketosis and major urinary bicarbonate loss. The kidney biopsy revealed nuclear and cytoplasmic accumulation of glycogen in proximal tubule cells, a lack of expression of GLUT2, and major defects of key proteins of the proximal tubule such as megalin, cubilin and the B2 subunit of H(+)-ATPase. These profound alterations of the transport systems most likely contributed to proximal tubule alterations and profound bicarbonate loss.

Published
2014

134. Timing of onset of CKD-related metabolic complications

Author

Moranne, Olivier, Froissart, Marc, Rossert, Jérôme, Gauci, Cédric, Boffa, Jean-Jacques, Haymann, Jean-Philippe, M'Rad, Mona Ben, Jacquot, Christian, Houillier, Pascal, Stengel, Bénédicte, Fouqueray, Bruno, Recherche en épidémiologie et biostatistique, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de physiologie, explorations fonctionnelles et radioisotopes [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Remodelage et Reparation du Tissu Renal, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Néphrologie et Hémodialyse [CHU HEGP], faculté de médecine, Université Pierre et Marie Curie - Paris 6 (UPMC), The NephroTest Study Group, Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Centre de Recherche des Cordeliers ( CRC (UMR_S 872) ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris Descartes - Faculté de Médecine ( UPD5 Médecine ), Université Paris Descartes - Paris 5 ( UPD5 ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de néphrologie, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Service de Physiologie [Tenon], Université Pierre et Marie Curie - Paris 6 ( UPMC ), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
metabolic acidosis, MESH: Anemia, MESH: Hyperparathyroidism, MESH : Prevalence, MESH : Male, MESH : Anemia, MESH : Aged, MESH: Acidosis, urologic and male genital diseases, MESH: Hyperphosphatemia, hyperparathyroidism, MESH : Chronic Disease, MESH : Middle Aged, MESH : Female, hyperphosphatemia, MESH: Prevalence, MESH: Aged, MESH: Kidney Diseases, MESH: Middle Aged, MESH: Humans, MESH : Hyperparathyroidism, MESH: Chronic Disease, MESH : Humans, MESH: Time Factors, MESH : Glomerular Filtration Rate, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Adult, MESH : Hyperkalemia, MESH : Adult, hyperkalemia, anemia, female genital diseases and pregnancy complications, MESH: Male, MESH: Odds Ratio, MESH: Glomerular Filtration Rate, MESH : Hyperphosphatemia, MESH : Kidney Diseases, MESH: Hyperkalemia, MESH : Odds Ratio, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Acidosis, MESH: Female, chronic kidney disease, MESH : Time Factors
Abstract

International audience; Chronic kidney disease (CKD) guidelines recommend evaluating patients with GFR

Published
2009

135. Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study.

Author

Wagner, Sandra, Metzger, Marie, Flamant, Martin, Houillier, Pascal, Haymann, Jean-Philippe, Vrtovsnik, François, Thervet, Eric, Boffa, Jean-Jacques, Massy, Ziad A., Stenge, Bénédicte, Rossignol, Patrick, Stengel, Bénédicte, and NephroTest Study group

Subjects
POTASSIUM, KIDNEY diseases, GLOMERULAR filtration rate, KIDNEY function tests, ANGIOTENSINS, TREATMENT of chronic kidney failure, CHRONIC kidney failure, LONGITUDINAL method, MORTALITY
Abstract

Background: Low and high blood potassium levels are common and were both associated with poor outcomes in patients with chronic kidney disease (CKD). Whether such relationships may be altered in CKD patients receiving optimized nephrologist care is unknown.Methods: NephroTest is a hospital-based prospective cohort study that enrolled 2078 nondialysis patients (mean age: 59 ± 15 years, 66% men) in CKD stages 1 to 5 who underwent repeated extensive renal tests including plasma potassium (PK) and glomerular filtration rate (GFR) measured (mGFR) by 51Cr-EDTA renal clearance. Test reports included a reminder of recommended targets for each abnormal value to guide treatment adjustment. Main outcomes were cardiovascular (CV) and all-cause mortality before end-stage kidney disease (ESKD), and ESKD.Results: At baseline, median mGFR was 38.4 mL/min/1.73m2; prevalence of low PK (<4 mmol/L) was 26.5%, and of high PK (>5 mmol/L) 6.4%; 74.4% of patients used angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). After excluding 137 patients with baseline GFR < 10 mL/min/1.73m2 or lost to follow-up, 459 ESKD events and 236 deaths before ESKD (83 CV deaths) occurred during a median follow-up of 5 years. Compared to patients with PK within [4, 5] mmol/L at baseline, those with low PK had hazard ratios (HRs) [95% CI] for all-cause and CV mortality before ESKD, and for ESKD of 0.82 [0.58-1.16], 1.01 [0.52-1.95], and 1.14 [0.89-1.47], respectively, with corresponding figures for those with high PK of 0.79 [0.48-1.32], 1.5 [0.69-3.3], and 0.92 [0.70-1.21]. Considering time-varying PK did not materially change these findings, except for the HR of ESKD associated with high PK, 1.39 [1.09-1.78]. Among 1190 patients with at least two visits, PK had normalized at the second visit in 39.9 and 54.1% respectively of those with baseline low and high PK. Among those with low PK that normalized, ARB or ACEi use increased between the visits (68.3% vs 81.8%, P < .0001), and among those with high PK that normalized, potassium-binding resin and bicarbonate use increased (13.0% vs 37.0%, P < .001, and 4.4% vs 17.4%, P = 0.01, respectively) without decreased ACEi or ARB use.Conclusion: In these patients under nephrology care, neither low nor high PK was associated with excess mortality. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

139. Increased risk of solid renal tumors in lithium-treated patients

Author

Zaidan, Mohamad, primary, Stucker, Fabien, additional, Stengel, Bénédicte, additional, Vasiliu, Viorel, additional, Hummel, Aurélie, additional, Landais, Paul, additional, Boffa, Jean-Jacques, additional, Ronco, Pierre, additional, Grünfeld, Jean-Pierre, additional, and Servais, Aude, additional

Published
2014
Full Text
View/download PDF

140. Développement professionnel continu (DPC) : ce que le néphrologue doit savoir

Author

Moulin, Bruno, primary, Frimat, Luc, additional, Bataille, Pierre, additional, Boffa, Jean-Jacques, additional, Brasseur, José, additional, Combe, Christian, additional, Joly, Dominique, additional, Laville, Maurice, additional, Mercadal, Lucile, additional, Peraldi, Marie-Noëlle, additional, Rieu, Philippe, additional, Vanhille, Philippe, additional, and Véla, Carlos, additional

Published
2014
Full Text
View/download PDF

142. Angiotensin II Activates Collagen Type I Gene in the Renal Vasculature of Transgenic Mice During Inhibition of Nitric Oxide Synthesis

Author

Boffa, Jean-Jacques, Tharaux, Pierre-Louis, Placier, Sandrine, Ardaillou, Raymond, Dussaule, Jean-Claude, Chatziantoniou, Christos, Tharaux, Pierre-Louis, U489 Inserm [CHU Tenon, APHP], Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Tenon [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
[SDV] Life Sciences [q-bio], [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, [SDV]Life Sciences [q-bio], [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Background —Hypertension is frequently associated with renal vascular fibrosis. The purpose of this study was to investigate whether angiotensin II (Ang II) is involved in this fibrogenic process. Methods and Results —Experiments were performed on transgenic mice harboring the luciferase gene under the control of the collagen I-α 2 chain promoter [procolα 2 (I)]. Hypertension was induced by chronic inhibition of NO synthesis ( N G -nitro- l -arginine methyl ester, L-NAME). Procolα 2 (I) activity started to increase in the renal vasculature after 4 weeks of L-NAME treatment ( P

Published
1999

147. Clinicopathological study of glomerular diseases associated with sarcoidosis: a multicenter study

Author

Stehlé, Thomas, primary, Joly, Dominique, additional, Vanhille, Philippe, additional, Boffa, Jean-Jacques, additional, Rémy, Philippe, additional, Mesnard, Laurent, additional, Hoffmann, Maxime, additional, Grimbert, Philippe, additional, Choukroun, Gabriel, additional, Vrtovsnik, François, additional, Verine, Jérôme, additional, Desvaux, Dominique, additional, Walker, Francine, additional, Lang, Philippe, additional, Mahevas, Matthieu, additional, Sahali, Dil, additional, and Audard, Vincent, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results